Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Dexamethasone
  • Glucocorticoids
  • Immunologic Factors
  • Multiple Myeloma
  • Thalidomide

abstract

  • Lenalidomide plus dexamethasone is superior to placebo plus dexamethasone in patients with relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00056160 [ClinicalTrials.gov].).

publication date

  • November 22, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa070596

PubMed ID

  • 18032763

Additional Document Info

start page

  • 2133

end page

  • 42

volume

  • 357

number

  • 21